SCHEMBL383740

SCHEMBL383740

CC(C)c1cc(C(=O)O)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.55
GLRA1 P23415 2/20 0.52
MCL1 Q07820 3/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RXRA P19793 1/20 0.48
PTGER1 P34995 3/20 0.48
MRGPRX4 Q96LA9 2/20 0.47
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
MAOB P27338 1/20 0.46
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383729 0.90 MAOB (0.55) FOLH1GLRA1MCL1L3MBTL1RXRA
SCHEMBL12941391 0.89 RXRA (0.51) FOLH1GLRA1MCL1KDM4EALDH1A1
SCHEMBL382283 0.89 GLRA1 (0.60) FOLH1GLRA1MCL1L3MBTL1RXRA
SCHEMBL4566984 0.89 MCL1 (0.54) FOLH1GLRA1MCL1KDM4EALDH1A1
SCHEMBL1148717 0.88 GLRA1 (0.49) GLRA1ALDH1A1RXRACTSVCTSL
SCHEMBL184621 0.88 RAB9A (0.52) FOLH1POLBRXRAMRGPRX4
SCHEMBL31363066 0.88 GLRA1 (0.49) GLRA1KDM4EALDH1A1POLBL3MBTL1
SCHEMBL30779557 0.84 SGMS2 (0.62) GLRA1ALDH1A1L3MBTL1MAOBMEN1
SCHEMBL21644687 0.84 SGMS2 (0.62) ALDH1A1MEN1KMT2A
SCHEMBL21644540 0.84 SGMS2 (0.62) GLRA1ALDH1A1L3MBTL1MAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709721-A1 DUAL EZH2-HSP90 INHIBITORS Taipei Medical University (TW) 2026-03-18 EP disclosed
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY MAGICBULLETTHERAPEUTICS CO., LTD. (KR) 2025-05-01 US disclosed
CN-119100970-A Bivalent inhibitor based on heat shock protein 90 and preparation method and application thereof 中国药科大学 2024-12-10 CN disclosed
US-20240398823-A1 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 TAIPEI MEDICAL UNIVERSITY (TW) 2024-12-05 US disclosed
WO-2024238381-A1 DUAL EZH2-HSP90 INHIBITORS TAIPEI MEDICAL UNIVERSITY (TW) 2024-11-21 WO disclosed
EP-4442691-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY Magicbullettherapeutics Co., Ltd. (KR) 2024-10-09 EP disclosed
CN-118613486-A 2, 7-Substituted pyrrolo [2,1-F ] [1,2,4] triazine compounds having protein kinase inhibitory activity 魔法弹丸治疗 2024-09-06 CN disclosed
EP-4399198-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 Taipei Medical University (TW) 2024-07-17 EP disclosed
CN-111164074-B Heat shock protein 90 inhibitors 台北医学大学 2024-02-02 CN disclosed
WO-2023140629-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY 닥터아이앤비(주) 2023-07-27 WO disclosed
US-20070276026-A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2007-11-29 US disclosed
EP-1857446-A1 NOVEL HSP90 INHIBITOR Nippon Kayaku Kabushiki Kaisha (JP) 2007-11-21 EP disclosed
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma ASTEX THERAPEUTICS, LTD. (GB) 2007-11-08 US disclosed
US-20070259871-A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 US disclosed
US-20070259871-A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 US disclosed
WO-2007094819-A2 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP. (US) 2007-08-23 WO disclosed
US-20070155809-A1 Triazole compounds that modulate HSP90 activity LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2007-07-05 US disclosed
US-20070155809-A1 Triazole compounds that modulate HSP90 activity LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2007-07-05 US disclosed
WO-2006109075-A2 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2006-10-19 WO disclosed
WO-2006109085-A1 HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 ASTEX THERAPEUTICS LIMITED (GB) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276026-A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 HSP90AB1, HSP90AB2P, HSP90AA1 FOLH1 4750/4885GLRA1 503/4885MCL1 2528/4885
US-20070259886-A1 (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma HSP90AB2P, HSP90AA1, HSP90AB1 FOLH1 4191/4885GLRA1 2422/4885MCL1 18/4885
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY STK25, MAP3K15, MAP3K5 FOLH1 3402/4885GLRA1 3741/4885MCL1 1135/4885
US-20070155809-A1 Triazole compounds that modulate HSP90 activity HSP90AB1, HSP90B1, HSP90AA1 FOLH1 4212/4885GLRA1 3902/4885MCL1 90/4885
US-20070259871-A1 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 HSP90AB1, HSP90AB2P, HSP90AA1 FOLH1 4751/4885GLRA1 497/4885MCL1 2540/4885
US-20240398823-A1 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 HSP90AB1, HDAC6, HSP90AB2P FOLH1 2885/4885GLRA1 3861/4885MCL1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.